10.6084/m9.figshare.3439757 Sundar Jagannath Sundar Jagannath Anuja Roy Anuja Roy Jonathan Kish Jonathan Kish Orsolya Lunacsek Orsolya Lunacsek Denise Globe Denise Globe Michael Eaddy Michael Eaddy Emil T. Kuriakose Emil T. Kuriakose Joanne Willey Joanne Willey Stephanie Butler-Bird Stephanie Butler-Bird David Siegel David Siegel Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices Taylor & Francis Group 2016 Multiple myeloma treatment patterns real-world evidence relapsed/refractory duration of therapy progression-free survival 2016-06-16 23:09:44 Dataset https://tandf.figshare.com/articles/dataset/Real-world_treatment_patterns_and_associated_progression-free_survival_in_relapsed_refractory_multiple_myeloma_among_US_community_oncology_practices/3439757 <p><b>Background</b>: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking.</p> <p><b>Methods</b>: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics.</p> <p><b>Results</b>: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1<sup>st</sup> (11.1 months) and 2<sup>nd</sup> line (10.5) and decreased in lines 3 through 5 (3<sup>rd</sup>: 7.9; 4<sup>th</sup>: 7.2, 5<sup>th</sup>: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months).</p> <p><b>Conclusions</b>: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.</p>